uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
KTH Royal Inst Technol, Sch Biotechnol, Div Prot Technol, Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medical Radiation Science. Affibody AB, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Biotechnol, Div Prot Technol, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Biotechnol, Div Prot Technol, Stockholm, Sweden..
2016 (English)In: mAbs, ISSN 1942-0862, E-ISSN 1942-0870, Vol. 8, no 7, 1195-1209 p.Article, review/survey (Refereed) Published
Abstract [en]

The human epidermal growth factor receptor 3 (HER3) has in recent years been recognized as a key node in the complex signaling network of many different cancers. It is implicated in de novo and acquired resistance against therapies targeting other growth factor receptors, e.g., EGFR, HER2, and it is a major activator of the PI3K/Akt signaling pathway. Consequently, HER3 has attracted substantial attention, and is today a key target for drugs in clinical development. Sophisticated protein engineering approaches have enabled the generation of a range of different affinity proteins targeting this receptor, including antibodies and alternative scaffolds that are either mono- or bispecific. Here, we describe HER3 and its role as a key tumor target, and give a comprehensive review of HER3-targeted proteins currently in development, including discussions on the opportunities and challenges of targeting this receptor.

Place, publisher, year, edition, pages
2016. Vol. 8, no 7, 1195-1209 p.
Keyword [en]
Affibody molecules, alternative scaffolds, bispecific antibodies, ErbB3, HER3, monoclonal antibodies, protein therapeutics, tumor targeting
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:uu:diva-309512DOI: 10.1080/19420862.2016.1212147ISI: 000385569400002PubMedID: 27532938OAI: oai:DiVA.org:uu-309512DiVA: diva2:1051910
Available from: 2016-12-05 Created: 2016-12-05 Last updated: 2016-12-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Frejd, Fredrik Y.
By organisation
Medical Radiation Science
In the same journal
mAbs
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 124 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf